<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167957</url>
  </required_header>
  <id_info>
    <org_study_id>MB-70008</org_study_id>
    <nct_id>NCT03167957</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis</brief_title>
  <official_title>A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matinas BioPharma Nanotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Matinas BioPharma Nanotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB
      dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB
      dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).

      Approximately 16 women with fluconazole-resistant VVC will be randomized to either 200 mg or
      400 mg oral CAMB for 14 days. The primary objectives of this study are to assess the clinical
      cure rate, mycology eradication and responder outcome. The secondary objective of this study
      is to evaluate the safety of 200 mg and 400 mg doses of oral CAMB.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with clinical cure at the Test of Cure visit</measure>
    <time_frame>28 days</time_frame>
    <description>Resolution of the VVC signs and symptoms that were present at baseline without further antifungal treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects with mycological eradication at the Test of Cure visit</measure>
    <time_frame>28 days</time_frame>
    <description>Negative culture for growth of baseline Candida</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Safety assessments include laboratory assessments, vital signs and physical exam</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Vulvovaginal Candidiases</condition>
  <condition>Yeast Infection</condition>
  <condition>Vulvovaginitis</condition>
  <condition>Yeast Infection Vaginal</condition>
  <condition>Candidiasis, Vulvovaginal</condition>
  <arm_group>
    <arm_group_label>CAMB 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg CAMB Oral Amphotericin B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAMB 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg CAMB Oral Amphotericin B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Encochleated Amphotericin B (CAMB)</intervention_name>
    <description>Lipid-crystal nano-particle formulation amphotericin B</description>
    <arm_group_label>CAMB 200 mg</arm_group_label>
    <other_name>MAT2203</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Encochleated Amphotericin B (CAMB)</intervention_name>
    <description>Lipid-crystal nano-particle formulation amphotericin B</description>
    <arm_group_label>CAMB 400 mg</arm_group_label>
    <other_name>MAT2203</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female 18-65 years

          -  Informed Consent

          -  Clinical diagnosis of fluconazole-resistant VVC

          -  Negative pregnancy test

          -  Vaginal pH â‰¤ 4.5

        Exclusion Criteria:

          -  Intolerance or hypersensitivity to any amphotericin B (AMB) product or to azole
             antifungal drugs

          -  Receiving antifungal therapy unrelated to VVC or has evidence of systemic fungal
             infections requiring antifungal therapy

          -  Received antifungal treatment for VVC within past 10 days except fluconazole, subjects
             must discontinue fluconazole after informed consent

          -  Has another cause or suspected cause of vulvovaginitis

          -  Has active HPV

          -  Has other urogenital infection

          -  Has other vaginal or vulvar condition that would confound interpretation of clinical
             response

          -  Has significant laboratory abnormality at screening

          -  Has Type I diabetes, use of insulin, HbA1c&gt;10

          -  Exposure to any investigational product within 30 days of screening

          -  Has other condition that would interfere with subject ability to provide informed
             consent or put subject at undue risk
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Douglas Kling</last_name>
    <phone>908-240-2005</phone>
    <email>dkling@matinasbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tolan Park Clinic</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jack D Sobel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fluconazole</keyword>
  <keyword>fluconazole-resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Vulvovaginitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

